ABRYSVOの市場規模、予測、市場考察：2032年

薬剤のサマリー

Pfizerの治験中のRSVワクチン候補であるABRYSVO（RSVpreF）は、RSVがヒト細胞を攻撃するために使用するウイルス融合タンパク質（F）の主な形態であるプレフュージョンFの結晶構造を詳述したNIHでの研究など、基礎科学の基礎的発見に基づいています。NIHの研究では、プレフュージョンに特異的な抗体がウイルス感染を阻止するのに非常に有効であることが示され、プレフュージョンFをベースとするワクチンがRSVに対する最適な防御をもたらす可能性が示されました。この重要な発見の後、Pfizerはこのウイルスタンパク質の多くのバージョンをテストし、前臨床の評価で強力な抗ウイルス免疫反応を引き起こすものを特定しました。このワクチン候補は、RSV AおよびBに対する防御を最適化するために選択された2つのpreFタンパク質で構成されています。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における呼吸器合胞体ウイルス（RSV）向けABRYSVOについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 RSVにおけるABRYSVOの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 ABRYSVO市場の評価

• RSVにおけるABRYSVOの市場見通し
• 主要7市場の分析
  • 主要7市場のRSV向けABRYSVOの市場規模
• 市場の分析：国別
  • 米国のRSV向けABRYSVOの市場規模
  • ドイツのRSV向けABRYSVOの市場規模
  • 英国のRSV向けABRYSVOの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ABRYSVO, Clinical Trial Description, 2023
• Table 2: ABRYSVO, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: ABRYSVO Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ABRYSVO Market Size in the US, in USD million (2019-2032)
• Table 7: ABRYSVO Market Size in Germany, in USD million (2019-2032)
• Table 8: ABRYSVO Market Size in France, in USD million (2019-2032)
• Table 9: ABRYSVO Market Size in Italy, in USD million (2019-2032)
• Table 10: ABRYSVO Market Size in Spain, in USD million (2019-2032)
• Table 11: ABRYSVO Market Size in the UK, in USD million (2019-2032)
• Table 12: ABRYSVO Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ABRYSVO Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ABRYSVO Market Size in the United States, USD million (2019-2032)
• Figure 3: ABRYSVO Market Size in Germany, USD million (2019-2032)
• Figure 4: ABRYSVO Market Size in France, USD million (2019-2032)
• Figure 5: ABRYSVO Market Size in Italy, USD million (2019-2032)
• Figure 6: ABRYSVO Market Size in Spain, USD million (2019-2032)
• Figure 7: ABRYSVO Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ABRYSVO Market Size in Japan, USD million (2019-2032)

"ABRYSVO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ABRYSVO for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the ABRYSVO for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ABRYSVO for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABRYSVO market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

Pfizer's investigational RSV vaccine candidate, ABRYSVO (RSVpreF), builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. The NIH research showed that antibodies specific to the prefusion form were highly effective at blocking virus infection, suggesting a prefusion F-based vaccine may confer optimal protection against RSV. After this important discovery, Pfizer tested numerous versions of the viral protein and identified those that elicited a strong antiviral immune response in preclinical evaluation. The vaccine candidate comprises two preF proteins selected to optimize protection against RSV A and B. Currently, the company is investigating this vaccine in many Phase III clinical trials.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ABRYSVO description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on ABRYSVO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABRYSVO research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ABRYSVO.
• The report contains forecasted sales of ABRYSVO for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for ABRYSVO in RSV.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ABRYSVO Analytical Perspective by DelveInsight

• In-depth ABRYSVO Market Assessment

This report provides a detailed market assessment of ABRYSVO for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ABRYSVO Clinical Assessment

The report provides the clinical trials information of ABRYSVO for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABRYSVO dominance.
• Other emerging products for RSV are expected to give tough market competition to ABRYSVO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABRYSVO in RSV.
• Our in-depth analysis of the forecasted sales data of ABRYSVO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABRYSVO in RSV.

Key Questions:

• What is the product type, route of administration and mechanism of action of ABRYSVO?
• What is the clinical trial status of the study related to ABRYSVO in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABRYSVO development?
• What are the key designations that have been granted to ABRYSVO for RSV?
• What is the forecasted market scenario of ABRYSVO for RSV?
• What are the forecasted sales of ABRYSVO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ABRYSVO for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

Table of Contents

1. Report Introduction

2. ABRYSVO Overview in RSV

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ABRYSVO Market Assessment

• 5.1. Market Outlook of ABRYSVO in RSV
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ABRYSVO in the 7MM for RSV
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ABRYSVO in the United States for RSV
  • 5.3.2. Market Size of ABRYSVO in Germany for RSV
  • 5.3.3. Market Size of ABRYSVO in France for RSV
  • 5.3.4. Market Size of ABRYSVO in Italy for RSV
  • 5.3.5. Market Size of ABRYSVO in Spain for RSV
  • 5.3.6. Market Size of ABRYSVO in the United Kingdom for RSV
  • 5.3.7. Market Size of ABRYSVO in Japan for RSV

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options